Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232400 | 0.86 | HPGD (0.46) | MEN1KMT2ALTC4SSMN1; SMN2MAPT | |
| SCHEMBL229926 | 0.86 | MEN1 (0.57) | MEN1KMT2ARECQLSMN1; SMN2MAPT | |
| SCHEMBL229900 | 0.83 | TUBB4A (0.45) | MEN1KMT2ALTC4SSMN1; SMN2MAPT | |
| SCHEMBL230032 | 0.83 | MAPT (0.44) | MEN1KMT2ALTC4SSMN1; SMN2MAPT | |
| SCHEMBL232232 | 0.82 | LMNA (0.50) | MEN1KMT2ALTC4SSMN1; SMN2MAPT | |
| SCHEMBL8762477 | 0.81 | HTT (0.59) | MEN1KMT2ARECQLSMN1; SMN2MAPT | |
| SCHEMBL231732 | 0.79 | MEN1 (0.51) | MEN1KMT2ARECQLSMN1; SMN2MAPT | |
| SCHEMBL27776291 | 0.79 | ALOX5 (0.56) | MEN1KMT2ARECQLSMN1; SMN2MAPT | |
| SCHEMBL232108 | 0.78 | MAPT (0.44) | MEN1KMT2ALTC4SSMN1; SMN2MAPT | |
| SCHEMBL231253 | 0.78 | LMNA (0.46) | MEN1KMT2ALTC4SSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102341371-A | As LTC4Bis-aromatic compounds as synthase inhibitors | BIOLIPOX AB (SE) | 2012-02-01 | — | — | CN | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | MEN1 4355/4885KMT2A 4283/4885RECQL 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.